Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03004105
Title MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center

lung non-small cell carcinoma


Durvalumab + Selumetinib

Age Groups: adult | senior
Covered Countries

No variant requirements are available.